Armistice Capital’s Decoy Therapeutics DCOY Stock Holding History

Armistice Capital’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-126	Closed	-$54.1K	–	316
2024 Q2	$54.1K	Buy	126 +68	+117%	+$44.9K	﹤0.01%	237
2024 Q1	$44.4K	Sell	58 -3	-5%	-$2.58K	﹤0.01%	315
2023 Q4	$57.2K	Sell	61 -95	-61%	-$94.8K	﹤0.01%	262
2023 Q3	$148K	Buy	156 +80	+105%	+$106K	﹤0.01%	211
2023 Q2	$163K	Buy	+76	New	+$174K	﹤0.01%	183

Other funds holding DCOY

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital's DCOY Position: Q3 2024 in Review

Armistice Capital sold out of Decoy Therapeutics (DCOY) in Q3 2024, closing a stake of 126 shares — an estimated $54.1K sold.

Armistice Capital first reported a position in DCOY in Q2 2023 and held it in 5 quarters. The position peaked at $163K in Q2 2023. 4 funds tracked by Wall St. Rank hold DCOY as of Q3 2024.

Armistice Capital reported no remaining Decoy Therapeutics position as of Q3 2024 after selling out during the quarter.
Armistice Capital sold 126 Decoy Therapeutics shares in Q3 2024, an estimated $54.1K.
Armistice Capital first reported a position in Decoy Therapeutics in Q2 2023 and held it in 5 quarters.
Armistice Capital's Decoy Therapeutics position peaked at $163K in Q2 2023.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.